These observations suggest that most of the trials of insulin and of non‐insulin T2DM therapies not using diagnostic biomarkers likely have included 15%–40% of participants who lack the biology of AD; the canonical biology of AD—Aβ plaque formation—is absent in these amyloid negative participants. Here, INS is linked to type 2 diabetes mellitus.